Eli Lilly and Company announced an additional $4.5 billion investment in its Lebanon, Indiana manufacturing facilities. This brings the company's total commitment in the state to over $21 billion since 2020.
The funding will expand production capacity for current medicines and the company's evolving pipeline. It specifically targets two facilities: a recently opened genetic medicine site and an active pharmaceutical ingredients (API) plant.
The API facility will produce ingredients for blockbuster tirzepatide treatments Mounjaro and Zepbound. It will also manufacture Foundayo, a new oral GLP-1 treatment, and the investigational drug retatrutide.